Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Subcutaneous OCTA101 in Severe Hemophilia A
NCT04046848Phase 2Terminated
- Sponsor
- Octapharma
- Start
- Jul 2019
- Primary completion
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of octa101 in hemophilia A, sponsored by Octapharma. Started Jul 2019; status: terminated.
02
Drugs
octa101
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT04046848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04046848.